Citius Oncology Prepares for LYMPHIR Launch Amid Strategic Review
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Citius Oncology, Inc. (Nasdaq: CTOR) is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies. As of June 27, 2025, CTOR shares traded on the Nasdaq (“NAS”) at $5.07, reflecting a 44.86 percent increase with a trading volume of 3,700,578 shares. The company’s principal asset is LYMPHIR™ (denileukin diftitox-cxdl), an FDA-approved immunotherapy for relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL).
Corporate Structure and Team
Citius Oncology is a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR). Citius Pharmaceuticals employs between 11 and 50 professionals across research, development, and commercial functions. At Citius Oncology, Leonard Mazur serves as Chairman and Chief Executive Officer, overseeing clinical, manufacturing, and commercialization efforts. The company is headquartered in Cranford, New Jersey.
Oncology Therapy by National Cancer Institute
Recent Developments and News
On January 6, 2025, Citius Oncology retained Jefferies LLC as exclusive financial advisor to evaluate strategic alternatives, including partnerships, joint ventures, mergers, acquisitions, and licensing agreements, to enhance shareholder value.
On February 14, 2025, the company reported financial results for the fiscal first quarter ended December 31, 2024, and provided a business update:
- Prepared for the LYMPHIR launch in the first half of 2025, with sufficient inventory on hand and additional production underway.
- Assignment of a permanent J-code (J9161) by the Centers for Medicare & Medicaid Services, effective April 1, 2025.
- Support for two investigator-initiated Phase I trials at the University of Pittsburgh Medical Center (combining LYMPHIR with pembrolizumab) and at the University of Minnesota (denileukin diftitox prior to CAR-T therapy), with interim results shared at the Society for Immunotherapy of Cancer Conference.
In June 2025, the company entered into a distribution services agreement with Cardinal Health to facilitate access and reimbursement for LYMPHIR in anticipation of its U.S. commercial launch in the second half of 2025.
Financial and Strategic Analysis
The following table compares key operating expenses and net loss for the fiscal first quarters ended December 31, 2024, and 2023:
| Metric | Q1 FY2025 (Dec 31, 2024) | Q1 FY2024 (Dec 31, 2023) |
|---|---|---|
| R&D expenses | $1.3 million | $1.2 million |
| G&A expenses | $3.3 million | $1.5 million |
| Stock-based compensation | $1.8 million | $1.9 million |
| Net loss (per share) | $6.7 million (-$0.09) | $4.7 million (-$0.07) |
The company’s net loss increased year-over-year, primarily due to higher general and administrative expenses. Engaging Jefferies indicates a strategic initiative to explore potential value-enhancing transactions. The assignment of a permanent J-code and its inclusion in National Comprehensive Cancer Network (NCCN) guidelines are steps supporting market access and reimbursement ahead of the LYMPHIR launch.
Market Position and Industry Context
LYMPHIR is the first systemic targeted therapy for CTCL approved since 2018 and is the only agent that selectively binds the interleukin-2 receptor. Management estimates the initial U.S. market opportunity at over $400 million, citing unmet needs in CTCL. The immuno-oncology sector features expanding combination approaches; Citius Oncology’s investigator-initiated trials aim to evaluate LYMPHIR's application alongside checkpoint inhibitors and CAR-T therapies. The distribution partnership with Cardinal Health addresses logistical and reimbursement pathways, supporting the company’s commercial efforts.
tl;dr
Citius Oncology engaged Jefferies on January 6, 2025, to assess strategic alternatives while preparing for the U.S. launch of LYMPHIR in the second half of 2025. On February 14, 2025, the company reported a Q1 net loss of $6.7 million, increased from $4.7 million, driven by higher G&A expenses. A permanent J-code (J9161) effective April 1, 2025, and a distribution agreement with Cardinal Health facilitate market access. Ongoing Phase I trials at the University of Pittsburgh and the University of Minnesota may broaden LYMPHIR’s application in combination immuno-oncology therapies.